Kezar Life Sciences, Inc. KZR NASDAQ

NASDAQ Global Select • Healthcare • Biotechnology • US • USD

SharesGrow Score

33/100

1/6 Pass

SharesGrow Intrinsic Value

SharesGrow 7-Criteria Score All 7 criteria scored · valuation-related highlighted on this page

Kezar Life Sciences, Inc. (KZR) has a negative trailing P/E of -1.0, meaning the company is currently unprofitable on a trailing twelve-month (TTM) basis. Trailing earnings yield is -103.84%.

Criteria proven by this page:

VALUE (20/100, Fail) — negative P/E indicates the company is currently operating at a loss — DCF and P/E-based valuation models cannot produce meaningful results for unprofitable companies (P/E -1.0); trailing earnings yield is below the 10-year Treasury yield (~4.3%), meaning bonds offer a better return (EY -103.84%); analyst consensus target implies downside from the current price ($6.00, 18.5%).
Trailing Earnings Yield -103.84% — negative yield confirms the company is currently unprofitable. Investors are paying for a turnaround rather than current earnings.
Analyst consensus target $6.00 (-18.5% downside) — analysts see meaningful downside risk at the current price level.

Overall SharesGrow Score: 32/100 with 1/7 criteria passed.

SharesGrow 7-Criteria Score

33/100

SG Score

View full scorecard →

✗

VALUE

20/100

Price-to-Earnings & upside

Proven by this page

✗

FUTURE

16/100

Analyst consensus

→ Forecast

✗

PAST

0/100

→ Income

✓

HEALTH

100/100

Debt-to-Equity & liquidity

→ Health

MOAT

46/100

→ Income

✗

GROWTH

15/100

→ Income

—

INCOME

N/A

No coverage

Valuation Snapshot — KZR

Valuation Multiples

P/E (TTM)-1.0

Forward P/EN/A

PEG RatioN/A

Forward PEGN/A

P/B Ratio0.77

P/S Ratio0.00

EV/EBITDA0.3

Per Share Data

EPS (TTM)$-7.66

Book Value / Share$9.58

Revenue / Share$0.00

FCF / Share$-7.08

Yields & Fair Value

Earnings Yield-103.84%

Dividend Yield0.00%

Analyst Target$6.00 (-18.5%)

Historical Valuation

Year	P/E (TTM)	PEG Ratio	P/B Ratio	P/S Ratio	Dividend Yield
2016	-2,570.8	0.00	-1,326.11	0.00	-
2017	-2,713.6	468.09	-899.73	0.00	-
2018	-1,937.9	-22.10	412.66	0.00	-
2019	-218.1	-6.19	98.05	0.00	-
2020	-550.3	12.97	162.93	0.00	-
2021	-1,614.7	-170.45	448.07	0.00	-
2022	-695.0	240.94	175.74	0.00	-
2023	-67.4	-1.75	36.63	981.55	-
2024	-5.9	0.33	4.19	0.00	-
2025	-0.8	0.00	0.66	0.00	-

EPS: Actual vs Estimates

P/E Ratio & Earnings Yield

Earnings Per Share (EPS) History

Year	EPS (Diluted)	Revenue	Net Income	Net Margin
2016	$-0.69	$0.00	$-8.99M	-
2017	$-0.65	$0.00	$-8.52M	-
2018	$-1.22	$0.00	$-23.17M	-
2019	$-1.65	$0.00	$-31.53M	-
2020	$-0.89	$0.00	$-38.99M	-
2021	$-1.01	$0.00	$-53.28M	-
2022	$-0.97	$0.00	$-65.32M	-
2023	$-1.40	$7M	$-101.87M	-1455.3%
2024	$-1.15	$0.00	$-83.74M	-
2025	$-7.66	$0.00	$-56.03M	-

Analyst Estimates

Year	EPS (Avg)	EPS Range	Revenue (Avg)	Revenue Range	Analysts
2026	$-4.74	$-7.58 – $-1.91	$0.00	$0.00 – $0.00	2
2027	$-4.59	$-6.70 – $-2.46	$21M	$21M – $21M	3
2028	$-4.70	$-11.49 – $-0.11	$31.5M	$31.5M – $31.5M	4
2029	$-4.09	$-4.09 – $-4.09	$19.97M	$19.97M – $19.97M	2
2030	$-6.10	$-6.10 – $-6.10	$20.73M	$20.73M – $20.73M	2